Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Surface Oncology, Inc. (SURF)
|
Add to portfolio |
|
|
|
| Price: |
$4.96
| | Metrics |
| OS: |
60.7
|
M
| |
|
|
| Market cap: |
$301
|
M
| |
|
|
|
Net cash:
|
$76.3
|
M
| |
$1.26
|
per share
|
|
EV:
|
$225
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 30.0 | 2.7 | 126.2 | 15.4 | 59.4 | 12.8 | 6.6 |
| Revenue growth | 1016.5% | -97.9% | 721.4% | -74.1% | 363.3% | 93.4% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 30.0 | 2.7 | 126.2 | 15.4 | 59.4 | 12.8 | 6.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 67.0 | 53.6 | 41.0 | 52.1 | 52.5 | 47.8 | 20.5 |
| General and administrative | 24.9 | 25.1 | 23.6 | 20.6 | 16.1 | 11.0 | 4.1 |
| EBIT | -61.9 | -76.0 | 61.6 | -57.4 | -9.2 | -46.0 | -18.0 |
| EBIT margin | -206.2% | -2828.9% | 48.8% | -373.5% | -15.4% | -358.6% | -271.5% |
| Pre-tax income | -63.6 | -78.5 | 59.3 | -54.8 | -6.6 | -45.4 | -17.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -63.6 | -78.5 | 59.3 | -54.8 | -6.6 | -45.4 | -17.5 |
| Net margin | -212.0% | -2920.9% | 47.0% | -356.7% | -11.1% | -354.1% | -263.8% |
| |
| Diluted EPS | ($1.14) | ($1.77) | $1.56 | ($1.97) | ($0.33) | ($18.35) | ($7.31) |
| Shares outstanding (diluted) | 55.8 | 44.2 | 38.1 | 27.9 | 20.0 | 2.5 | 2.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|